Orion Oyj
OMXH:ORNBV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
32.27
49.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Orion Oyj
Investor Relations
Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission.
Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.
Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission.
Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.
You don't have any saved screeners yet
